Use of atypical antipsychotics in the elderly.

Recent research on dementia patients suggests that use of antipsychotics may increase risk of hospitalization or death. While bipolar disorder and schizophrenia combine to represent more than 70 percent of atypical antipsychotic uses in younger patients, these same indications represent only 38 percent of product use in patients age 65 and older. The difference between the two age groups is driven primarily by use in cognitive impairment: Dementia and Alzheimer's combine to account for 28 percent of atypical antipsychotic use in older patients. Although ICD-9 coding tends to group patients into less specific diagnoses, we did isolate a small group of approximately 10 percent of patients that were classified based on the presence or absence of behavior disturbances. Eighteen percent of dementia patients without behavioral disturbances received atypical antipsychotics as compared to 66 percent of patients with behavioral disturbances. A discussion of the results is provided.

[1]  Jeffrey Cummings,et al.  Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. , 2008, The Journal of clinical psychiatry.

[2]  S. Gauthier,et al.  Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis , 2008, International journal of geriatric psychiatry.

[3]  D. Jeste,et al.  ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia , 2008, Neuropsychopharmacology.

[4]  A. Egberts,et al.  Antipsychotic Drug Use and Risk of Pneumonia in Elderly People , 2008, Journal of the American Geriatrics Society.

[5]  J. Mintzer,et al.  Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. , 2007, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[6]  M. Valenstein,et al.  Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. , 2007, The American journal of psychiatry.

[7]  P. Tariot,et al.  Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. , 2007, Current Alzheimer research.

[8]  N. Herrmann,et al.  A Placebo-Controlled Trial of Valproate for Agitation and Aggression in Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[9]  Daniel Weintraub,et al.  Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. , 2006, The New England journal of medicine.

[10]  J. Avorn,et al.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications. , 2005, The New England journal of medicine.

[11]  L. Schneider,et al.  Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[12]  Lon S Schneider,et al.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.

[13]  P. Deyn,et al.  Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone , 2005, Clinical Neurology and Neurosurgery.

[14]  J. Cummings,et al.  Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies , 2006, Nature Reviews Drug Discovery.